Skip to main content

12/08/22

Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium

In The News

Media

STX-478, a mutant-selection PI3Kα inhibitor clinical candidate with a best-in-class-profile

Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile

Discovery and characterization of a PI3KαH1047X mutant selective inhibitor with a best-in-class profile

Press Releases